Brief: Zynerba Pharmaceuticals Provides Regulatory Update On Zygel In Fragile X Syndrome

Zynerba Pharmaceuticals

17/12/2020 11:34

Dec 17 (Reuters) - Zynerba Pharmaceuticals Inc  ZYNE.O :
    * ZYNERBA PHARMACEUTICALS PROVIDES REGULATORY UPDATE ON
ZYGEL™ IN
FRAGILE X SYNDROME
    * ZYNERBA PHARMACEUTICALS - PLANS TO CONDUCT
PLACEBO-CONTROLLED
PIVOTAL TRIAL IN PATIENTS WITH FXS WHO HAVE HIGHLY METHYLATED
FMR1 GENE
    * ZYNERBA PHARMACEUTICALS INC - EXPECTS THAT ITS CASH RUNWAY
WILL
EXTEND INTO BEGINNING OF 2023 AS A RESULT OF THESE CHANGES TO
ITS DEVELOPMENT PLANS
    * ZYNERBA PHARMACEUTICALS - IN H1 2021, TO REVIEW ZYGEL
TRIAL
DESIGN, PROTOCOL FOR NEW TRIAL THROUGH TYPE C MEETING WITH FDA
    * ZYNERBA PHARMACEUTICALS - EXPECTS TO INITIATE ZYGEL
PIVOTAL
TRIAL BEFORE END OF 2021

Source text for Eikon:  ID:nGNX1q3mV7 
Further company coverage:  ZYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))